Crosby T, Fish R, Coles B, Mason M
Cochrane Database Syst Rev. 2018; 2:CD001215.
PMID: 29411867
PMC: 6491111.
DOI: 10.1002/14651858.CD001215.pub2.
Kushnir I, Merimsky O
Oncol Lett. 2013; 5(2):424-426.
PMID: 23420786
PMC: 3573132.
DOI: 10.3892/ol.2012.1065.
Turley R, Raymond A, Tyler D
Surg Oncol Clin N Am. 2010; 20(1):79-103.
PMID: 21111960
PMC: 3023884.
DOI: 10.1016/j.soc.2010.09.008.
Yang A, Chapman P
Hematol Oncol Clin North Am. 2009; 23(3):583-97, x.
PMID: 19464604
PMC: 3904102.
DOI: 10.1016/j.hoc.2009.03.006.
Einzig A, Schuchter L, Recio A, Coatsworth S, Rodriquez R, Wiernik P
Med Oncol. 1996; 13(2):111-7.
PMID: 9013474
DOI: 10.1007/BF02993861.
An inverse relationship between the growth rate of human melanoma xenografts and their response to some cytostatic drugs.
Fodstad O, Aass N, Pihl A
Br J Cancer. 1980; 41(5):829-31.
PMID: 7426308
PMC: 2010311.
DOI: 10.1038/bjc.1980.149.
Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma.
Amato D, Bruckner H, Guerry 4th D, Ash A, FALKSON G, Borden E
Invest New Drugs. 1987; 5(3):293-7.
PMID: 3667165
DOI: 10.1007/BF00175301.
Treatment of advanced malignant melanoma with coumarin and cimetidine: a pilot study.
MARSHALL M, Butler K, Cantrell J, Wiseman C, Mendelsohn L
Cancer Chemother Pharmacol. 1989; 24(1):65-6.
PMID: 2720893
DOI: 10.1007/BF00254109.
Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study.
Ringborg U, RUDENSTAM C, Hansson J, Hafstrom L, Stenstam B, Strander H
Med Oncol Tumor Pharmacother. 1989; 6(4):285-9.
PMID: 2693850
DOI: 10.1007/BF02985163.
Phase II study of carboplatin and cytosine arabinoside in patients with disseminated malignant melanoma.
Mulder N, Sleijfer D, De Vries E, Schraffordt Koops H, Willemse P
J Cancer Res Clin Oncol. 1990; 116(3):301-2.
PMID: 2196265
DOI: 10.1007/BF01612907.
Antineoplastic drugs in 1990. A review (Part II).
Black D, Livingston R
Drugs. 1990; 39(5):652-73.
PMID: 2191847
DOI: 10.2165/00003495-199039050-00003.
Carboplatinum and cytosine arabinoside in patients with disseminated malignant melanoma. A phase II study.
Jeremic B, Djuric L, Mijatovic L
Invest New Drugs. 1991; 9(3):277-80.
PMID: 1783529
DOI: 10.1007/BF00176984.
Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.
CURRIE G, McElwain T
Br J Cancer. 1975; 31(2):143-56.
PMID: 1164466
PMC: 2009407.
DOI: 10.1038/bjc.1975.19.
Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.
Newlands E, Oon C, Roberts J, Elliott P, Mould R, Topham C
Br J Cancer. 1976; 34(2):174-9.
PMID: 962994
PMC: 2025153.
DOI: 10.1038/bjc.1976.140.
Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence.
Hedley D, McElwain T, CURRIE G
Br J Cancer. 1978; 37(4):491-6.
PMID: 646922
PMC: 2009555.
DOI: 10.1038/bjc.1978.76.
[In vitro and in vivo sensitivity of animal and human melanomas to various chemotherapeutical agents].
WISKEMANN A, Schussmann M, Rothmann D, Schneider O
Arch Dermatol Res. 1978; 262(3):285-99.
PMID: 568919
DOI: 10.1007/BF00447365.
Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma.
Frosch P, Czarnetzki B, Macher E, Grundmann E, Gottschalk I
J Cancer Res Clin Oncol. 1979; 95(3):281-6.
PMID: 528568
DOI: 10.1007/BF00410649.
Monocytes and macrophages in malignant melanoma IV. Effects of C. parvum on monocyte function.
Hedley D, Nyholm R, CURRIE G
Br J Cancer. 1979; 39(5):558-65.
PMID: 486312
PMC: 2009899.
DOI: 10.1038/bjc.1979.101.
Temperature and host defense.
Roberts Jr N
Microbiol Rev. 1979; 43(2):241-59.
PMID: 390356
PMC: 281473.
DOI: 10.1128/mr.43.2.241-259.1979.
Chemotherapy of malignant melanoma.
Benjamin R
World J Surg. 1979; 3(3):321-8.
PMID: 382646
DOI: 10.1007/BF01556584.
